Researchers have developed an algorithm capable of predicting low blood pressure that could occur during surgery with 84 percent accuracy. Findings were published June 11 in Anesthesiology.

Despite claims otherwise from President Donald Trump, the Affordable Care Act remains the law of the land—though federal actions have increased instability in the ACA’s marketplaces. Following last year’s repeal of the individual mandate, insurers are now offering short-term, non-ACA-compliant policies, which could leave a sicker, older population shopping on ACA marketplaces.

Officials from HHS are currently talking with pharmaceutical companies to pursue voluntary price cuts as part of President Donald Trump’s drug pricing plan, The Hill reports.

For every 10 percent rise in negative social media encounters, individuals experience a 20 percent increase in their risk of depression, according to a study published June 6 in Depression and Anxiety.

Pediatrician Mona Hanna-Attisha, MD, recounts her experiences during the Flint water crisis in 2015—and how she discovered children were being poisoned—in an article published in The New York Times.

Nearly three-fourths of life science professionals believe their sector is behind others in the development of artificial intelligence (AI), according to a survey conducted by the Pistoia Alliance.

Researchers from Brigham and Women's Hospital in Boston have developed “surgery in a pill” to treat type 2 diabetes by lowering blood glucose levels after a meal. The newly developed approach was outlined in a study published June 11 in Nature Materials.

Five months before the 2018 midterm elections, California Republicans see their opponents’ embrace of exploring single-payer healthcare as an opportunity.

On Monday, June 11, CMS released guidance for states to leverage Medicaid in fighting opioid abuse and misuse—with the document making specific mention of efforts to reduce negative impact in infants and outlining potential benefits of health information technology.

Private equity firm KKR & Co. announced its plan to buy Envision Healthcare for $5.57 billion and debt. The all-cash transaction will value Envision at $9.9 billion, according to Bloomberg.